Alaunos Therapeutics Inc
TCRT
Company Profile
Business description
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Contact
501 East Las Olas Boulevard
Suite 300
Fort LauderdaleFL33301
USAT: +1 346 355-4099
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1
Stocks News & Analysis
stocks
ASX gold miner overvalued despite stronger gold prices
Higher gold prices boosted profit yet shares remain materially overvalued.
stocks
ASX energy giant undervalued despite commissioning challenges
Near-term hurdles, long-term upside.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,199.70 | 30.70 | 0.33% |
| CAC 40 | 8,398.31 | 60.47 | -0.71% |
| DAX 40 | 25,502.99 | 38.98 | 0.15% |
| Dow JONES (US) | 52,747.32 | 537.24 | 1.03% |
| FTSE 100 | 10,895.23 | 24.21 | 0.22% |
| HKSE | 25,807.92 | 497.07 | 1.96% |
| NASDAQ | 24,876.91 | 55.17 | -0.22% |
| Nikkei 225 | 61,434.19 | 930.73 | -1.49% |
| NZX 50 Index | 13,976.67 | 114.74 | 0.83% |
| S&P 500 | 7,428.78 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,038.60 | 35.10 | 0.39% |
| SSE Composite Index | 3,828.47 | 15.15 | 0.40% |